Perioperative alpha blockers in voiding dysfunction secondary to prostate biopsy: A meta-analysis

IF 1.6 Q3 UROLOGY & NEPHROLOGY BJUI compass Pub Date : 2024-05-08 DOI:10.1002/bco2.366
Sean Lim, Kylie Yen-Yi Lim, Liang Qu, Sanjeeva Ranasinha, Anthony Dat, Matthew Brown, Paul Manohar, Matthew Harper, Scott Donnellan, Weranja Ranasinghe
{"title":"Perioperative alpha blockers in voiding dysfunction secondary to prostate biopsy: A meta-analysis","authors":"Sean Lim,&nbsp;Kylie Yen-Yi Lim,&nbsp;Liang Qu,&nbsp;Sanjeeva Ranasinha,&nbsp;Anthony Dat,&nbsp;Matthew Brown,&nbsp;Paul Manohar,&nbsp;Matthew Harper,&nbsp;Scott Donnellan,&nbsp;Weranja Ranasinghe","doi":"10.1002/bco2.366","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction and Objectives</h3>\n \n <p>Voiding dysfunction remains a common side effect postprostate biopsy leading to significant morbidity. Alpha blockers have emerged as a potential therapeutic option to mitigate this risk, with various centres already incorporating its use in practice. Despite this, the literature regarding its efficacy remains inconclusive. Hence, a systematic review was performed to quantify the effect of perioperative alpha blockers on prostate biopsy-related voiding function.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A systematic search in MEDLINE, Embase and PubMed between January 1989 and July 2023 was performed to identify relevant articles. Two independent reviewers independently screened abstracts, full texts and performed data extraction. Data including International Prostate Symptom Scores (IPSS), voiding flow rates (Qmax), postvoid residuals (PVR), rates of acute urinary retention (AUR) and quality of life (QoL) scores were extracted. Results were combined in an inverse variance random effects meta-analysis.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total 808 patients from six randomised controlled trials (RCTs) comparing alpha blockers to controls were included. All articles excluded patients with pre-existing voiding dysfunction. Pooled outcomes demonstrated statistically significant differences favouring alpha blocker usage in all objective and subjective measures including IPSS (mean difference 4.21, 95% confidence interval [CI] 2.58–5.84, <i>p &lt;</i> 0.00001), PVR (mean difference 20.41 mL, 95% CI 3.44–37.39, <i>p =</i> 0.02), Qmax (mean difference 3.07 mL/s, 95% CI 2.55–3.59, <i>p &lt;</i> 0.00001), QoL (weighted-mean difference 0.82, CI 0.17–1.48, <i>p =</i> 0.01) as well as overall risk of AUR (odds ratio 0.22, CI 0.09–0.55, <i>p =</i> 0.001). There was variable heterogeneity (<i>I</i><sup>2</sup> = 0–86%) between outcomes.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>This review highlights the potential role of alpha blockers in improving urinary function and reducing adverse voiding outcomes postprostate biopsy. The standard practice of incorporating the usage of perioperative alpha blockers may be considered to reduce the morbidity of voiding complications secondary to prostate biopsy.</p>\n </section>\n </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"5 8","pages":"748-760"},"PeriodicalIF":1.6000,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.366","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BJUI compass","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/bco2.366","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction and Objectives

Voiding dysfunction remains a common side effect postprostate biopsy leading to significant morbidity. Alpha blockers have emerged as a potential therapeutic option to mitigate this risk, with various centres already incorporating its use in practice. Despite this, the literature regarding its efficacy remains inconclusive. Hence, a systematic review was performed to quantify the effect of perioperative alpha blockers on prostate biopsy-related voiding function.

Methods

A systematic search in MEDLINE, Embase and PubMed between January 1989 and July 2023 was performed to identify relevant articles. Two independent reviewers independently screened abstracts, full texts and performed data extraction. Data including International Prostate Symptom Scores (IPSS), voiding flow rates (Qmax), postvoid residuals (PVR), rates of acute urinary retention (AUR) and quality of life (QoL) scores were extracted. Results were combined in an inverse variance random effects meta-analysis.

Results

A total 808 patients from six randomised controlled trials (RCTs) comparing alpha blockers to controls were included. All articles excluded patients with pre-existing voiding dysfunction. Pooled outcomes demonstrated statistically significant differences favouring alpha blocker usage in all objective and subjective measures including IPSS (mean difference 4.21, 95% confidence interval [CI] 2.58–5.84, p < 0.00001), PVR (mean difference 20.41 mL, 95% CI 3.44–37.39, p = 0.02), Qmax (mean difference 3.07 mL/s, 95% CI 2.55–3.59, p < 0.00001), QoL (weighted-mean difference 0.82, CI 0.17–1.48, p = 0.01) as well as overall risk of AUR (odds ratio 0.22, CI 0.09–0.55, p = 0.001). There was variable heterogeneity (I2 = 0–86%) between outcomes.

Conclusions

This review highlights the potential role of alpha blockers in improving urinary function and reducing adverse voiding outcomes postprostate biopsy. The standard practice of incorporating the usage of perioperative alpha blockers may be considered to reduce the morbidity of voiding complications secondary to prostate biopsy.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
围手术期α受体阻滞剂治疗前列腺活检继发的排尿功能障碍:荟萃分析
排尿功能障碍仍然是前列腺活检术后常见的副作用,会导致严重的发病率。α受体阻滞剂已成为减轻这一风险的潜在治疗选择,许多中心已将其应用于实践中。尽管如此,有关其疗效的文献仍然没有定论。因此,我们进行了一项系统性综述,以量化围手术期α受体阻滞剂对前列腺活检相关排尿功能的影响。我们对1989年1月至2023年7月期间的MEDLINE、Embase和PubMed进行了系统性检索,以确定相关文章。两名独立审稿人分别独立筛选摘要、全文并进行数据提取。提取的数据包括国际前列腺症状评分(IPSS)、排尿流量(Qmax)、排尿后残余物(PVR)、急性尿潴留率(AUR)和生活质量(QoL)评分。六项随机对照试验(RCT)共纳入了808名患者,这些试验将α受体阻滞剂与对照组进行了比较。所有文章都排除了原有排尿功能障碍的患者。汇总结果表明,在所有客观和主观测量指标中,使用α受体阻滞剂均有显著统计学差异,包括IPSS(平均差异4.21,95% 置信区间[CI] 2.58-5.84,P < 0.00001)、PVR(平均差异20.41 mL,95% CI 3.44-37.39,p = 0.02)、Qmax(平均差异 3.07 mL/s,95% CI 2.55-3.59,p <0.00001)、QoL(加权平均差异 0.82,CI 0.17-1.48,p = 0.01)以及 AUR 的总体风险(几率比 0.22,CI 0.09-0.55,p = 0.001)。本综述强调了α受体阻滞剂在改善排尿功能和减少前列腺活检后不良排尿结果方面的潜在作用。可以考虑在围手术期使用α受体阻滞剂的标准做法,以降低前列腺活检术后排尿并发症的发病率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.30
自引率
0.00%
发文量
0
审稿时长
12 weeks
期刊最新文献
Issue Information Issue Information Reliability of mpMRI in diagnosing cancer prostate following intravesical BCG for bladder cancer Understanding the long-term impact of the COVID-19 pandemic on non-muscle-invasive bladder cancer outcomes: 12-Month follow-up data from the international, prospective COVIDSurg Cancer study Treatment preferences of patients with muscle invasive bladder cancer: A discrete choice experiment
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1